Martin Shkreli
Martin Shkreli is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare. He is the former chief executive officer of the pharmaceutical firms Retrophin and Turing Pharmaceuticals. In September 2015, he was widely criticized when Turing obtained the manufacturing license for the antiparasitic drug Daraprim and raised its price by a factor of 56. He...
